ClinicalTrials.gg
Not yet recruitingNCT05950516Updated Jul 18, 2023

Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes

A Phase 3 interventional study of Semaglutide and Semaglutide Pen Injector [Ozempic] in Type 2 Diabetes, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-07-18.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
478
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Planned enrollment
41st of 163
478 · median 104
Started
2023
with 19 others
Phase 3
57 of 163
7 open now
Primary completion
2024-11
later than 3 of 44 live
Registered
120th of 163
by date

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 41st largest by planned enrollment, is one of 20 that started in 2023, is one of 57 in phase 3, reaches primary completion later than 3 of the 44 other live ones, and was the 120th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To evaluate the similarity of the efficacy and safety of semaglutide injection (QLG2065) vs. Ozempic® in patients with type 2 diabetes mellitus (T2DM) with poor blood glucose control after metformin treatment.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age ≥ 18 years and ≤75 years old at the time of screening.
  2. Subjects diagnosed with type 2 diabetes for at least 6 months (WHO, 1999)
  3. Within 60 days before screening, subjects received stable treatment with only metformin ≥ 1500 mg/day (or maximum tolerated dose ≥ 1000 mg/day), or receive combination metformin (dose ≥ 750 mg/day) and another OAD (alpha-glucosidase inhibitors, sulfonylureas, glinides, SGLT-2i or thiazolidinedione), stable treatment is defined as unchanged medication and daily doses;
  4. At the time of screening, for those who have previously been treated with metformin alone, ≥ 7.0% and ≤ 11.0%(local lab); for those who have previously used metformin in combination with another OAD treatment, HbA1c ≥ 7.0% and ≤10.0%(local lab);
  5. ≥18.5kg/m2 and ≤35 kg/m2
  6. Subjects voluntarily participate in this research, can communicate well with researchers, are willing to maintain the same diet and exercise habits throughout the study, and sign an form (ICF) .
  7. At baseline,HbAlc ≥ 7.0% and ≤ 11.0%(cental lab)

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected to any GLP-1RA or related products, or allergic constitution
  2. Treatment with GLP-1RA, DPP-4 inhibitor, or insulin in a period of 60 days before screening. An exception is short-term insulin therapy (≤7 days in total).
  3. History of chronic or acute pancreatitis
  4. Screening calcitonin value ≥ 50 ng/L (pg/mL)
  5. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)
  6. Have a history of major cardiovascular and cerebrovascular diseases within 90 days before screening.
  7. Known proliferative retinopathy or maculopathy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
478 participants (estimated)

Study arms

  • Experimental
    QLG2065

    Up to 1.0 mg semaglutide (QLG2065) Metformin ≥ 1500 mg/day (or maximum tolerated dose ≥ 1000 mg/day).

    Drug: Semaglutide

  • Active comparator
    Ozempic

    Up to 1.0 mg semaglutide (Ozempic) Metformin ≥ 1500 mg/day (or maximum tolerated dose ≥ 1000 mg/day).

    Drug: Semaglutide Pen Injector [Ozempic]

Interventions

  • Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks

    Also known as: QLG2065

  • Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks

    Also known as: Ozempic Injectable Product

06

What researchers measure

Primary outcomes

  1. Change in HbA1c

    Change from baseline (week 1) to week 33 in glycosylated haemoglobin (HbA1c) was evaluated

    Time frame: Week 33

Secondary outcomes

  1. Change in HbA1c

    Change from baseline (week 1) to week 21 in glycosylated haemoglobin (HbA1c) was evaluated

    Time frame: Week 21

  2. Percentage of Participants Who Achieved HbA1c <7.0% , HbA1c ≤6.5%

    Percentage of participants who achieved HbA1c \< 7.0%, HbA1c ≤6.5% is presented

    Time frame: Week 21, 33

  3. Change in Fasting Glucose

    Change from baseline (week 1) to week 21, 33 in Fasting Glucose was evaluated

    Time frame: Week 21, 33

  4. Change in Body Weight

    Change from baseline (week 1) to week 21, 33 in body weight was evaluated

    Time frame: Week 21, 33

  5. Percentage of Participants That Achieved Body Weight Loss ≥5%

    Percentage of participants losing ≥5% of baseline body weight is presented

    Time frame: Week 21, 33

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2023; primary completion for Nov 2024, 16 months later.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 16 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2023
First posted
Jul 18, 2023
StartEst.
Jul 10, 2023
Primary completionEst.
Nov 24, 2024
CompletionEst.
Jan 22, 2025
Last update
Jul 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05950516
Responsible party
Sponsor
First posted
Jul 18, 2023
Start date
Jul 10, 2023 (estimated)
Primary completion
Nov 24, 2024 (estimated)
Completion
Jan 22, 2025 (estimated)
Last update
Jul 18, 2023

Study contacts

Chuanzheng Han
Contact
chuanzheng2.han@qilu-pharma.com
0531-55821374
Jiajun Zhao
principal investigator · Shandong Provincial Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion